Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.

Spindeldreher, Sebastian; Maillère, Bernard; Correia, Evelyne; Tenon, Maxime; Karle, Anette; Jarvis, Philip; Kolbinger, Frank

Spindeldreher, Sebastian; Maillère, Bernard; Correia, Evelyne; Tenon, Maxime; Karle, Anette; Jarvis, Philip; Kolbinger, Frank.

Afiliación

Spindeldreher S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. Sebastian.Spindeldreher@novartis.com.
Maillère B; CEA-Saclay, Institut Frédéric Joliot, SIMOPRO, Université Paris-Saclay, 91191, Gif-Sur-Yvette, France.
Correia E; CEA-Saclay, Institut Frédéric Joliot, SIMOPRO, Université Paris-Saclay, 91191, Gif-Sur-Yvette, France.
Tenon M; CEA-Saclay, Institut Frédéric Joliot, SIMOPRO, Université Paris-Saclay, 91191, Gif-Sur-Yvette, France.
Karle A; Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Novartis Pharma AG, Basel, Switzerland.
Jarvis P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
Kolbinger F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Dermatol Ther (Heidelb) ; 8(2): 327, 2018 06.

Article en En | MEDLINE | ID: mdl-29551008

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2018 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google